<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077050</url>
  </required_header>
  <id_info>
    <org_study_id>SIMPS</org_study_id>
    <nct_id>NCT01077050</nct_id>
  </id_info>
  <brief_title>SciBase International Melanoma Pivotal Study</brief_title>
  <official_title>SciBase International Melanoma Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciBase AB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SciBase AB</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation was to determine the safety and effectiveness of
      the SciBase III device (Test) designed to help distinguish between malignant melanoma and
      benign lesions, using electrical impedance spectroscopy (EIS) relative to the histological
      gold standard (Reference).

      The purpose of the study is to collect data to support a Pre-market Application(PMA) to
      obtain Food and Drug Administration(FDA) approval to market the SciBase III Electrical
      Impedance Spectrometer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SciBase Sensitivity and Specificity</measure>
    <time_frame>Post data lock</time_frame>
    <description>This study has two co-primary objectives, aiming to demonstrate the accuracy of SciBase device:
Sensitivity ≥ 0.90 to detect Melanoma
Sensitivity - (1-Specificity) &gt; 0.00
Sensitivity is the proportion of correctly identified cases of Melanoma. Specificity is the proportion of correctly identified cases of non-melanoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>Post data lock</time_frame>
    <description>Secondary confirmatory objective included two co-secondary endpoints that were defined similarly to the co-primary endpoints, but used the Secondary definition of dichotomous reference diagnosis.
Positive Reference Diagnosis: Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Severe Dysplastic Nevus (High grade dysplasia)
Negative Reference Diagnosis: All other skin lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1951</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>SciBase III</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SciBase III Electrical Impedance Spectrometer</intervention_name>
    <description>SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.</description>
    <arm_group_label>SciBase III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        For inclusion in the study, all subjects had to fulfill all of the following criteria:

          -  Men or women of any ethnic group aged ≥18 years

          -  Primary lesions (i.e., not metastases or recurrent lesions) that the physicians choose
             to excise.

          -  Lesion ≥ 2 mm in diameter and ≤ 20 mm in diameter

          -  In subjects with multiple skin lesions, all lesions destined for excision must be
             identified for purposes of study participation. Note: a subject may only be entered
             into the study once.

          -  The subject is willing and able to read, understand and sign the study specific
             informed consent form.

        Exclusion Criteria:

        Subjects were excluded from the study if they fulfilled any of the following criteria:

          -  Skin surface not measurable, e.g. lesion on a stalk

          -  Skin surface not accessible, e.g. inside ears, under nails

          -  Lesion located on acral skin, e.g. sole or palms.

          -  Lesion located on areas of scars, crusts, psoriasis, eczema or similar skin
             conditions.

          -  Lesion on hair-covered areas, e.g. scalp, beards, moustaches or whiskers.

          -  Lesion located on genitalia.

          -  Lesion located in an area that has been previously biopsied or subjected to any kind
             of surgical intervention or traumatized.

          -  Lesion located on mucosal surfaces.

          -  Skin is not intact (measurement area) e.g. bleeding or with clinical noticeable
             ulceration.

          -  Lesion with foreign matter, e.g. tattoo, splinter

          -  Lesion and/or reference located on acute sunburn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik H Birgersson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>SciBase and Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aberg P, Nicander I, Holmgren U, Geladi P, Ollmar S. Assessment of skin lesions and skin cancer using simple electrical impedance indices. Skin Res Technol. 2003 Aug;9(3):257-61.</citation>
    <PMID>12877688</PMID>
  </reference>
  <reference>
    <citation>Aberg P, Nicander I, Hansson J, Geladi P, Holmgren U, Ollmar S. Skin cancer identification using multifrequency electrical impedance--a potential screening tool. IEEE Trans Biomed Eng. 2004 Dec;51(12):2097-102.</citation>
    <PMID>15605856</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>June 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted at five (5) US investigational sites and at seventeen (17) European investigational sites.
Recruitment period 2010-2011. In 2012 the last histological analysis was performed.</recruitment_details>
      <pre_assignment_details>Potential study subjects were screened according to the inclusion/exclusion criteria. All study eligible skin lesion(s) were then examined with the investigational device, photographed and removed by an excisional biopsy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Only One Arm in the Study, Thus Not Applicable.</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1951"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1942"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects signed ICF could not be located</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.</population>
      <group_list>
        <group group_id="B1">
          <title>Biopsied Skin Lesions</title>
          <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1942"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SciBase Sensitivity and Specificity</title>
        <description>This study has two co-primary objectives, aiming to demonstrate the accuracy of SciBase device:
Sensitivity ≥ 0.90 to detect Melanoma
Sensitivity – (1-Specificity) &gt; 0.00
Sensitivity is the proportion of correctly identified cases of Melanoma. Specificity is the proportion of correctly identified cases of non-melanoma.</description>
        <time_frame>Post data lock</time_frame>
        <population>Biopsied Skin Lesions</population>
        <group_list>
          <group group_id="O1">
            <title>Biopsied Skin Lesions</title>
            <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
          </group>
        </group_list>
        <measure>
          <title>SciBase Sensitivity and Specificity</title>
          <description>This study has two co-primary objectives, aiming to demonstrate the accuracy of SciBase device:
Sensitivity ≥ 0.90 to detect Melanoma
Sensitivity – (1-Specificity) &gt; 0.00
Sensitivity is the proportion of correctly identified cases of Melanoma. Specificity is the proportion of correctly identified cases of non-melanoma.</description>
          <population>Biopsied Skin Lesions</population>
          <units>Percentage of total lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1611"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Biopsied Skin Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1943"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SciBase Sensitivity to melanoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="93.7" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SciBase Specificity to non-melanoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="29.2" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Sensitivity to Melanoma</param_type>
            <param_value>96.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>94.2</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Sensitivity to Basal Cell Carcinoma</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.6</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Observed sensitivity for squamous cell c</param_type>
            <param_value>93.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.1</ci_lower_limit>
            <ci_upper_limit>99.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Note that calculating odds ratio adjusting for subjects having multiple lesions, yields similar result.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.6</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity</title>
        <description>Secondary confirmatory objective included two co-secondary endpoints that were defined similarly to the co-primary endpoints, but used the Secondary definition of dichotomous reference diagnosis.
Positive Reference Diagnosis: Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Severe Dysplastic Nevus (High grade dysplasia)
Negative Reference Diagnosis: All other skin lesions.</description>
        <time_frame>Post data lock</time_frame>
        <posting_date>08/2013</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A post-procedure follow up, either by a telephone or investigational site visit, was to be conducted at 7 (seven) +/- 3 (three) days from the SciBase III evaluation, at which time the subject were to be evaluated for any adverse events.</time_frame>
      <desc>The Safety analysis population includes all subjects for whom there was any contact with subject's skin and the SciBase III investigational device. Therefore the number of subjects included in the safety analysis deviates from both the total number of enrolled and eligible subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Biopsied Skin Lesions</title>
          <description>Any adverse advent that occured on a skin/lesion site for whom there had been any contact between the subject's skin and investigational device (SciBase III).
Note that multiple adverse event occured on some subjects. In total 36 Adverse Events were reported on 28 subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neck and facial swelling after lymph node dissection</sub_title>
                <description>Suffered from neck and facial swelling 2 days after lymph node dissection surgery had been performed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Suffered from diarrhea</sub_title>
                <description>Suffered from diarrhea for two days after measurements and excision</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Suffered from a cold</sub_title>
                <description>Suffered from a cold for 3 days after the excision had been performed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experience nausea</sub_title>
                <description>Experience nausea for 2 days post measurement and excision</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Suture came out prematurely</sub_title>
                <description>One suture came out prematurely.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experienced sensation of fainting</sub_title>
                <description>Became pale and felt faint immediately following the biopsy. The subject felt much better after lying down and was able to leave the clinic under his own power.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experienced mild chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Experienced a headache/migrane post SciBase measurements and surgical excision.</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Experienced bleeding through the bandage after excision.</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Lesion started to bleed during examination/measurement</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experience of slight pain from excision</sub_title>
                <description>Experienced pain from the wound or excisional site.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experience of slight pain/pin pricks from probe</sub_title>
                <description>Experienced slight pain / pin pricks from the probe. Resolved once the probe was removed or measurements ended.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Experience of soreness/itch/tingling at excisional/measurement site</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Developed infection following excision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1915"/>
              </event>
              <event>
                <sub_title>Minimal brusing</sub_title>
                <description>Experienced very minimal bruising appeared on the measurement site approximately 10 minutes after four attempts had been made to obtain a device reading.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1915"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>SciBase</organization>
      <phone>+46841062001</phone>
      <email>per.svedenhag@scibase.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

